Adding tarlatamab to maintenance nearly doubled survival in small-cell lung cancer

Extensive-stage small-cell lung cancer is one of the hardest cancers to treat. It responds briskly to first-line chemotherapy combined with an immunotherapy drug, then almost always comes back, and median survival sits at roughly 12 to 13 months [s1]. A phase 3 trial published in the New England Journal of Medicine on 24 October tested whether a newer kind of immunotherapy, given during the quiet period after that first response, can hold the disease back for longer [s1].

What tarlatamab is

Tarlatamab is a bispecific T-cell engager: a single antibody with two grips, one that latches onto DLL3, a protein found on most small-cell lung cancer cells, and one that grabs CD3 on the patient's own T cells [s1]. By bridging the two, it drags immune cells directly onto the tumour. It was already shown to extend survival as a second-line treatment, after the cancer has progressed [s1]. DeLLphi-305 asked a different question: used earlier, as maintenance, could it keep patients in remission longer?

Maintenance here means treatment given after the initial chemoimmunotherapy has already brought the disease under control, to delay its return rather than to attack active disease. The comparator was durvalumab, an anti–PD-L1 antibody that is itself the current maintenance standard in this setting [s1].

How the trial was built

DeLLphi-305 was an international, open-label, randomised phase 3 trial, registered as NCT06211036 [s1][s2]. It enrolled patients with extensive-stage small-cell lung cancer whose disease had not progressed after initial chemoimmunotherapy, and randomly assigned 563 of them to one of two maintenance regimens: tarlatamab plus durvalumab (282 patients) or durvalumab alone (281 patients) [s1]. Both survival outcomes were measured from the point of randomisation, at the start of maintenance [s1]. Overall survival was the primary endpoint and progression-free survival the key secondary one [s1]. The results reported are a prespecified interim analysis, with a data cut-off of 7 July 2026 [s1].

What it found

The separation was large. At a median follow-up of about 16 months in each group, median overall survival was 21.1 months (95% CI 20.8 to not estimable) with tarlatamab plus durvalumab, against 12.7 months (95% CI 11.2–14.8) with durvalumab alone [s1]. The hazard ratio for death was 0.42 (95% CI 0.32–0.54; P<0.001) — a 58% lower rate of death over the follow-up so far [s1].

Progression-free survival moved even more sharply. The median was 7.4 months (95% CI 5.6–9.1) with the combination versus 1.9 months (95% CI 1.9–2.0) with durvalumab alone, a hazard ratio of 0.34 (95% CI 0.28–0.42; P<0.001) [s1]. In plain terms, on durvalumab alone the disease was typically progressing again within two months of starting maintenance; adding tarlatamab pushed that out to more than seven.

The cost side

That benefit came with added toxicity, as this class of drug does. Grade 3 or higher adverse events occurred in 46.8% of patients on the combination and 40.6% of those on durvalumab alone [s1]. The signature complication of T-cell engagers, cytokine release syndrome — a surge of immune signalling that can cause fever and low blood pressure — was seen in nearly half the patients on tarlatamab, though mainly at the milder grade 1 or 2 [s1]. Cytokine release syndrome is why tarlatamab is typically started under close monitoring.

What is, and is not, established

What the trial shows is that, in extensive-stage small-cell lung cancer controlled by first-line chemoimmunotherapy, adding tarlatamab to durvalumab maintenance substantially lengthens both the time to progression and overall survival, at the price of more side effects including frequent, mostly mild cytokine release syndrome [s1]. For a disease where progress has been slow for decades, a hazard ratio of 0.42 for death is a striking result.

The caveats are real. This is an interim analysis: the upper bound of the median survival estimate could not yet be calculated, and longer follow-up will firm up the numbers [s1]. The trial was open-label, and it reports a specific sequence — maintenance after a response to chemoimmunotherapy — not use in patients whose disease never responded [s1].

Red flags: patients receiving T-cell–engaging therapy who develop fever, dizziness, breathlessness or confusion should seek urgent medical care, as these can be signs of cytokine release syndrome. This article describes research and is not medical advice. Treatment choices in small-cell lung cancer are for patients and their oncology teams.